Following Liquidia?

Get the free weekly contract digest

The latest new contracts, like Liquidia’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Liquidia Corp's chief medical officer sells $31,785 in stock

Jan 24, 2025•over 1 year ago

Contract Type

contract

MorrisvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiotechnology Research

Description

The chief medical officer of Liquidia Corp has sold $31,785 in stock, representing a significant transaction within the company. This event may signify changes within the organization's leadership or financial strategy.

Company Information

Company

Liquidia

Location

Morrisville, North Carolina, United States

About

Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT® Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Our subsidiary, Liquidia PAH (formerly RareGen), generates revenue pursuant to a promotional agreement between RareGen and Sandoz, sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection, or Treprostinil Injection, in the United States.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Liquidia's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months